Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 11,249 shares, an increase of 596.5% from the January 29th total of 1,615 shares. Based on an average daily trading volume, of 11,160 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.2% of the company’s stock are sold short. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 11,160 shares, the days-to-cover ratio is currently 1.0 days.

Alterity Therapeutics Trading Down 1.7%

NASDAQ ATHE traded down $0.06 during trading on Friday, hitting $3.47. The stock had a trading volume of 4,705 shares, compared to its average volume of 11,700. Alterity Therapeutics has a 12 month low of $2.52 and a 12 month high of $7.00. The company’s 50-day moving average price is $3.31 and its two-hundred day moving average price is $3.94.

Alterity Therapeutics (NASDAQ:ATHE) last announced its quarterly earnings data on Friday, January 30th. The company reported ($0.18) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Alterity Therapeutics will post -0.34 earnings per share for the current fiscal year.

Institutional Trading of Alterity Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in Alterity Therapeutics during the 3rd quarter valued at approximately $83,000. HB Wealth Management LLC acquired a new stake in shares of Alterity Therapeutics during the third quarter worth $220,000. Greenleaf Trust raised its stake in Alterity Therapeutics by 88.2% during the third quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock worth $120,000 after buying an additional 15,000 shares during the last quarter. Finally, Twin Lakes Capital Management LLC lifted its holdings in Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after buying an additional 133,333 shares during the period. 2.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on ATHE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, January 21st. Canaccord Genuity Group began coverage on shares of Alterity Therapeutics in a report on Wednesday, December 17th. They set a “speculative buy” rating for the company. Finally, Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Alterity Therapeutics currently has an average rating of “Hold”.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.